Ra Pharma Aims For Oral Peptide Drugs Using Synthetic Amino Acids
This article was originally published in The Pink Sheet Daily
Executive Summary
Just out of stealth mode, privately held biotech closes second tranche of $27 million Series A financing and announces first drug program will pursue an oral kallikrein inhibitor for prevention of hereditary angioedema.